RxDoctor Payments Data

Alan Lau, MD

Internal Medicine · Los Angeles, CANPI 1396768446

Payments from drug & device makers

$1,241in general payments, 2019–2025

Across 51 payments — averaging $24.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$409
  • Novo Nordisk$178
  • Bayer$128
  • AstraZeneca$125
  • Corcept Therapeutics$110
  • Lilly USA, LLC$71
  • plus $221 from 8 others

What the payments were for

  • Food & beverage$1,241100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,241 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$23,732
Medicare patients
63
Services billed
183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin109$105,491
OzempicSemaglutide35$32,434
JanuviaSitagliptin Phosphate25$25,758
EliquisApixaban34$20,806
Diclofenac Sodium57$6,073
Losartan Potassium180$2,065
Atorvastatin Calcium170$1,575
Levothyroxine Sodium100$1,446
Tamsulosin Hcl104$1,428
Omeprazole103$1,242
Metformin Hcl162$1,094
Simvastatin168$1,074
Levetiracetam30$967
Duloxetine Hcl13$879
Finasteride50$838

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$409$105,491109 claims
Novo NordiskOzempic$178$32,43435 claims
PfizerEliquis$24$20,80634 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →